Thanks. I should note that my reactions to zipjet were of a general nature on his underlying assumptions that are just not valid in my view. My comments were not directed toward Lovenox per se or the investment worthiness of MNTA. With or without an AG, FDA approval of enoxaparin would certainly yield very nice returns to MNTA holders.
Market Data 
Markets 
AI
